Targets of hydroxychloroquine in the treatment of rheumatoid arthritis. A network pharmacology study.

Joint Bone Spine

Zhejiang Chinese medical university, The Third People's hospital of Hangzhou, West Lake road 38, 310009 Hangzhou, People's Republic of China. Electronic address:

Published: March 2021

Objective: This study was performed to investigate the multi-targets mechanism of hydroxychloroquine (HCQ) in the treatment of rheumatoid arthritis (RA).

Methods: The predicted targets of HCQ and the proteins related to RA were returned from databases. Followed by protein-protein interaction (PPI) network, the intersection of the two group of proteins was studied. Furthermore, gene ontology (GO) and KyotoEncyclopediaofGenesandGenomes (KEGG) enrichment was used to analyse these proteins in a macro perspective. Finally, the candidate targets were checked by molecular docking.

Results: The results suggested that HCQ in the treatment of RA was mainly associated with 4 targets that are smoothened homolog (SMO), sphingosine kinase (SPHK) 1, SPHK2 and gatty-acid amide hydrolase (FAAH), with their related 3276 proteins' network which regulate ErbB, HIF-1, NF-κB, FoxO, chemokines, MAPK, PI3K/Akt pathways and so forth. Biological process were mainly focused in the regulation of cell activation, myeloid leukocyte activation, regulated exocytosis and so forth. Molecular docking analysis showed that hydrogen bonding and π-π stacking were the main forms of chemical force.

Conclusions: Our research provides protein targets affected by HCQ in the treatment of RA. SMO, SPHK1, SPHK2 and FAAH involving 3276 proteins become the multi-targets mechanism of HCQ in the treatment of RA.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2020.105099DOI Listing

Publication Analysis

Top Keywords

hcq treatment
16
treatment rheumatoid
8
rheumatoid arthritis
8
multi-targets mechanism
8
targets hcq
8
targets
5
treatment
5
hcq
5
targets hydroxychloroquine
4
hydroxychloroquine treatment
4

Similar Publications

Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy.

Pharmaceutics

January 2025

Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.

Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. Despite advancements in treatment, complete remission remains elusive. In this study, we introduce a novel lipid nanoparticle formulation co-delivering hydroxychloroquine (HCQ) and siRNA targeting TNF-α (si) using microfluidic technology, marking the first use of such a combination for RA therapy.

View Article and Find Full Text PDF

Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.

Pharmaceutics

December 2024

Department of Experimental Therapeutics, BC Cancer, Vancouver, BC V5Z 1L3, Canada.

Preclinical studies have shown that the anti-malarial drug hydroxychloroquine (HCQ) improves the anti-cancer effects of various therapeutic agents by impairing autophagy. These findings are difficult to translate in vivo as reaching an effective HCQ concentration at the tumor site for extended times is challenging. Previously, we found that free HCQ in combination with gefitinib (Iressa, ZD1839) significantly reduced tumor volume in immunocompromised mice bearing gefitinib-resistant JIMT-1 breast cancer xenografts.

View Article and Find Full Text PDF

Various repurposing drugs have been tested for their efficacy on coronavirus disease 2019 (COVID-19), including antimalarial drugs. During the pandemic, Chloroquine (CQ) and Hydroxychloroquine (HCQ) demonstrated good potential against COVID-19, but further studies showed both drugs had side effects that were more dangerous than the efficacy. This made World Health Organization (WHO) ban the usage for COVID-19 patients.

View Article and Find Full Text PDF

Acquired Dyschromatopsia and Its Link to Drug Toxicity.

Cureus

December 2024

Optometric - Glaucoma, Leicester Royal Infirmary, Leicester, GBR.

Colour vision defects (CVDs) can be both congenital and acquired, with acquired dyschromatopsia often associated with medication toxicity. This review explores various standardised colour vision tests used to detect these defects, including the Ishihara plate test, Farnsworth-Munsell 100 hue test, and anomaloscopes. These methods are evaluated for their effectiveness in diagnosing CVDs, particularly in acquired conditions.

View Article and Find Full Text PDF

Background: Hydroxychloroquine and Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs with well-known anti-inflammatory and antiviral effects used to treat various diseases, with few side effects. After COVID-19 emergence, numerous researches from around the world have examined the potential of using CQ or HCQ as potential treatment of COVID-19. However, conflicting outcomes have been found in COVID-19 clinical trials after treatment with CQ or HCQ.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!